| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Mayinglong Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥25.99 |
| 52 Week High | CN¥32.20 |
| 52 Week Low | CN¥20.20 |
| Beta | 0.56 |
| 1 Month Change | 12.56% |
| 3 Month Change | 14.04% |
| 1 Year Change | 3.38% |
| 3 Year Change | 35.51% |
| 5 Year Change | 63.97% |
| Change since IPO | 1,039.94% |
Recent News & Updates
Shareholder Returns
| 600993 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.2% | -1.5% | -0.4% |
| 1Y | 3.4% | -16.0% | -17.6% |
Return vs Industry: 600993 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 600993 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 600993 volatility | |
|---|---|
| 600993 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 600993 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600993's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1582 | 3,241 | Youzhang Xia | www.mayinglong.cn |
Mayinglong Pharmaceutical Group Co., LTD. engages in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. The company products pipeline primarily consists of functional cosmetics, functional care products, functional food, and Chinese herbal medicines, as well as hemorrhoid, gynecological, cough, and skin products; and medical instruments.
Mayinglong Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 600993 fundamental statistics | |
|---|---|
| Market cap | CN¥11.20b |
| Earnings (TTM) | CN¥443.25m |
| Revenue (TTM) | CN¥3.14b |
25.3x
P/E Ratio3.6x
P/S RatioIs 600993 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600993 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.14b |
| Cost of Revenue | CN¥1.83b |
| Gross Profit | CN¥1.31b |
| Other Expenses | CN¥864.01m |
| Earnings | CN¥443.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 20, 2024
| Earnings per share (EPS) | 1.03 |
| Gross Margin | 41.68% |
| Net Profit Margin | 14.13% |
| Debt/Equity Ratio | 4.0% |
How did 600993 perform over the long term?
See historical performance and comparison